Repaglinide tablets are non-sulfonylurea insulin secretion agents and are used to treat patients with type 2 diabetes. Repaglinide tablets were listed in China in 2000, and it is a Class B drug in the National Medical Insurance List. Repaglinide tablets have been listed as a drug for diabetic patients with renal insufficiency by many guidelines at home and abroad.

Product name: Repaglinide Tablets

Characteristic: White or off-white tablet

Specification: repaglinide 0.5mg×30 tablets, repaglinide 0.5mg×60 tablets.

Indications：

It is used for type 2 diabetes (non-insulin-dependent) patients whose hyperglycemia cannot be effectively controlled by diet control, weight loss and exercise. When metformin alone cannot effectively control hyperglycemia, Repaglinide tablets can be combined with metformin. Treatment should start from the adjuvant treatment of diet control and exercise to reduce blood sugar during meals.

Specifications of repaglinide 0.5 mg tablet

Usage and Dosage，Adverse reactions，Contraindications，Precautions：

Please refer to the package insert.

Medicine Interactions:

Some drugs are known to affect glucose metabolism. Therefore, doctors should consider possible drug interactions.

In vitro studies have shown that the metabolism of Repaglinide is affected by CYP2C8 and CYP3A4. Repaglinide was found to be a substrate for active liver uptake (organic anion transporter OATP1B1).